Watch-and-wait OK in low-tumor burden follicular lymphomaMedical XpressAn initial watch-and-wait strategy does not have a detrimental effect on the freedom from treatment failure or overall survival rate in selected patients with low-tumor burden folli…
Watch & Wait OK in Low-Tumor Burden Follicular LymphomaDoctors LoungeAn initial watch-and-wait strategy does not have a detrimental effect on the freedom from treatment failure or overall survival rate in selected patients with low-tumor burden fol…
Cell Therapeutics' phase 1 study of pacritinib shows encouraging anti-tumour …pharmabiz.comPatients had relapsed following a median of five prior therapies (range 2-15); 44% had failed prior stem cell transplant and 52% were rituximab refractory….
Drugs and dollarsNews & ObserverDuke University Health System charged $32,370 for rituximab, which treats lymphoma and leukemia. Duke settled for $19,420. Medicare would have allowed $6,420. Duke received $10,670 for a dose of Neulasta, which fights in…
Tysabri Taking Biogen Idec To New HighsForbesFounded in 1985, Biogen has several candidates in its pipeline, including BG-12 (multiple sclerosis), daclizumab (multiple sclerosis), Factor VIII (hemophilia A) and Factor IX (hemophilia B) among others. So…
Cancer drug mark-ups bring in big money for NC nonprofit hospitalsKansas City StarCarolinas Medical Center-NorthEast in Concord was paid about $19,000 for a one-gram dose of rituximab, used to treat lymphoma and leukemia. That was roughly three times t…
Spectrum Pharmaceuticals Provides Update on Belinostat Registrational Trial …MarketWatch (press release)The ZEVALIN therapeutic regimen consists of two components: rituximab, and Yttrium-90 (Y-90) radiolabeled ZEVALIN for therapy. ZEVALIN builds on t…
Biogen Idec – MomentumNASDAQFounded in 1985, Biogen has several candidates in its pipeline, including BG-12 (multiple sclerosis), daclizumab (multiple sclerosis), Factor VIII (hemophilia A) and Factor IX (hemophilia B) among others. Want More of Our Be…
Newspaper: Hospitals inflate prices on chemo drugsSan Francisco ChronicleDuke University Medical Center received $19,420 for a course of rituximab, used to treat lymphoma and leukemia. Medicare would have allowed a maximum payment of $6,420. — Forsyt…
Prices soar as hospitals dominate cancer marketCharlotte ObserverCarolinas Medical Center-NorthEast in Concord was paid about $19,000 for a one-gram dose of rituximab, used to treat lymphoma and leukemia. That was roughly three times the average sales …